Literature DB >> 2252842

Stereoselective disposition of ibuprofen and flurbiprofen in rats.

R D Knihinicki1, R O Day, G G Graham, K M Williams.   

Abstract

(R)-2-Arylpropionates are often inverted to the pharmacologically active S-enantiomers in vivo, although there is significant interspecies variability in inversion. In order to provide a basis for determining the biochemical consequences of this unique process using rats as a model, it was important to establish the pharmacokinetic disposition of the enantiomers of ibuprofen, a drug well inverted in man and flurbiprofen, a drug apparently poorly inverted in man. Rats were dosed i.v. with a single dose of (R)- or (S)-ibuprofen (20 mg/kg), (R,S)-ibuprofen (40 mg/kg), (R)- or (S)-flurbiprofen (10 mg/kg), or (R,S)-flurbiprofen (20 mg/kg). Each treatment group consisted of six animals. Serial blood samples were withdrawn over a period of 6 h for ibuprofen and 10 h for flurbiprofen. These drugs were assayed in plasma by a stereospecific HPLC assay. The pharmacokinetics of the ibuprofen and flurbiprofen enantiomers were evaluated using a two-compartment open model with conversion of the R- to S-enantiomers in the central compartment. There was 50 +/- 4% inversion of (R)-ibuprofen, a figure similar to that observed in man and (R)-ibuprofen had a higher clearance (12.6 +/- 1.3 ml/min/kg) than (S)-ibuprofen (7.7 +/- 0.7 ml/min/kg; P less than 0.01). The clearance of (R)-flurbiprofen after racemate (2.3 +/- 0.1 ml/min/kg) was higher than its clearance when administered alone (1.7 +/- 0.2 ml/min/kg; P less than 0.01), indicating a pharmacokinetic interaction between the enantiomers (most probably at plasma protein binding sites). A corresponding difference was not observed for ibuprofen. There was a small amount of inversion of (R)-flurbiprofen as determined by area analysis (4.5 +/- 1.6%).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2252842     DOI: 10.1002/chir.530020303

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  6 in total

Review 1.  Preclinical and clinical development of dexketoprofen.

Authors:  D Mauleón; R Artigas; M L García; G Carganico
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of ibuprofen. The first 30 years.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

3.  The effects of liver and renal disease on stereoselective serum binding of flurbiprofen.

Authors:  R Blouin; I Chaudhary; K Nishihara; S Cox
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

4.  Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers.

Authors:  G Geisslinger; J Lötsch; S Menzel; G Kobal; K Brune
Journal:  Br J Clin Pharmacol       Date:  1994-04       Impact factor: 4.335

5.  Pharmacokinetics of the enantiomers of ibuprofen in the rabbit.

Authors:  K M Williams; R D Knihinicki; R O Day
Journal:  Agents Actions       Date:  1991-11

6.  Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation.

Authors:  Daniel J Hermanson; Nolan D Hartley; Joyonna Gamble-George; Naoko Brown; Brian C Shonesy; Phillip J Kingsley; Roger J Colbran; Jeffrey Reese; Lawrence J Marnett; Sachin Patel
Journal:  Nat Neurosci       Date:  2013-08-04       Impact factor: 24.884

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.